联环药业(600513.SH)：法莫替丁注射液获得《药品注册证书》

Core Viewpoint - Recently, Lianhuan Pharmaceutical (600513.SH) received approval from the National Medical Products Administration for the drug registration certificate of Famotidine Injection, which is a medication that works by inhibiting gastric acid secretion and belongs to the class of histamine H2 receptor antagonists [1] Company Summary - Lianhuan Pharmaceutical has successfully developed Famotidine Injection, expanding its product portfolio in the pharmaceutical market [1] - The approval of Famotidine Injection indicates the company's commitment to enhancing its therapeutic offerings in the gastrointestinal treatment sector [1] Industry Summary - The approval of new drugs like Famotidine Injection reflects ongoing advancements in the pharmaceutical industry, particularly in the development of medications for gastrointestinal disorders [1] - The introduction of histamine H2 receptor antagonists is significant for addressing conditions related to excessive gastric acid secretion, which is a common health issue [1]